Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017–August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ wa...
Saved in:
| Main Authors: | Raunak Parikh, David Singer, Elizabeth Chmielewski-Yee, Christophe Dessart |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2263979 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States
by: Ana Florea, et al.
Published: (2024-12-01) -
Disseminated herpes zoster encephalitis induced by low-dose corticosteroids
by: Natalie Soliman, BS, et al.
Published: (2025-09-01) -
Real-world effectiveness of recombinant herpes Zoster vaccine: a retrospective, cohort study in Japan
by: Satoko Ohfuji, et al.
Published: (2025-08-01) -
Prevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Recipients—A Single-Center Analysis
by: Ewa Karakulska-Prystupiuk, et al.
Published: (2025-05-01) -
The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide
by: Nikolaos Giannelos, et al.
Published: (2025-05-01)